Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026.
Ajax Therapeutics focuses on developing next-generation Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), particularly myelofibrosis, utilizing advanced computational chemistry and structural biology
Ajax Therapeutics focuses on developing next-generation Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), particularly myelofibrosis, utilizing advanced computational chemistry and structural biology.